Weak Acid Ionization at Body pH: What Actually Happens

When you dissolve a weak acid in an aqueous environment, the pH determines how much of it exists in ionized versus unionized form. At physiological pH of 7.4, most weak acids with a typical pKa between 3 and 5 are almost entirely deprotonated. This isn't theoretical, it's basic acid-base chemistry, but people in pharmacology and formulation science still get tripped up by the practical consequences. The Henderson-Hasselbalch equation governs this: pH = pKa + log([A-]/[HA]). For a carboxylic acid with pKa 4.5, plugging in 7.4 gives you a ratio of roughly 800:1 in favor of the ionized form. That means only about 0.12% remains unionized. Unionized molecules cross lipid membranes much more readily than charged ones. This single number is why aspirin gets absorbed primarily in the stomach rather than the small intestine despite the small intestine having far greater surface area. The pH gradient does the heavy lifting. I spent three days troubleshooting a solubility-stability compromise on a drug candidate last year because the formulation team didn't account for ionization at physiological pH. The compound was a weak acid with pKa 4.8. In simulated gastric fluid it was fine, fully dissolved. But once it hit the buffered intestinal fluid at pH 6.5, precipitation kicked in hard. The solution wasn't a polymer coating or a salt form, it was simply adjusting the dissolution media to include a small amount of bile salt surrogate. We ended up using 0.5% polysorbate 80 in the test media and the apparent solubility jumped from under 10 micrograms per milliliter to over 200. It's a frustrating thing to discover late in development.

Practical Implications for Absorption and Formulation

Weak acids with pKa below 5 will be predominantly ionized in blood and extracellular fluid. This has direct consequences for volume of distribution and protein binding. Ionized species bind to albumin more readily than unionized ones in many cases, which affects free drug concentration. If you're working with a weak acid drug, the fraction unbound in plasma can shift noticeably if the local pH changes even slightly. In conditions like acidosis where blood pH drops toward 7.2, the ionized fraction decreases, potentially increasing the free active concentration. This is clinically relevant for highly protein-bound acids like phenytoin or warfarin. For oral formulation, you need to think about what pH the drug encounters along its path. Stomach pH varies from 1 to 3 in fasting state but can rise to 4 or higher after a meal. Enteric coatings are designed to resist dissolution until pH reaches about 5.5 to 6.5, which means a weak acid drug in an enteric capsule will remain largely unionized inside the coating until it dissolves in the intestine. This creates a supersaturation window that can be either beneficial or problematic depending on the compound's intrinsic solubility. A common mistake I see is assuming that because a compound is a weak acid it must be absorbed in the stomach. The stomach has very limited surface area and constant motility that moves contents along quickly. Most absorption for weak acids still occurs in the duodenum and jejunum where the pH is closer to neutral and the surface area is orders of magnitude larger. The unionized fraction may be smaller, but the absolute amount absorbed per unit time is usually higher there. I've seen this confirmed repeatedly in in situ perfusion studies where the effective permeability multiplied by surface area clearly favors the proximal small intestine.

Calculating Ionization State Correctly

Many people reach for the Henderson-Hasselbalch equation and stop there. But the equation assumes ideal behavior, infinite dilution, and that activity coefficients equal one. In real biological fluids with ionic strength around 0.15 M, activity coefficients deviate significantly. The Debye-Hückel correction becomes relevant. For monovalent ions at physiological ionic strength, the activity coefficient is approximately 0.75. This means your effective pKa shifts by roughly 0.1 to 0.2 pH units depending on the charge state of your acid. For most early-stage screening this doesn't matter, but if you're building a PBPK model or predicting human pharmacokinetics from in vitro data, ignoring activity corrections can introduce meaningful error. Another issue is that physiological pH isn't uniform. The microclimate pH at the brush border membrane of enterocytes can differ from bulk luminal pH by up to 1.5 pH units due to unstirred water layers and mucosal buffering. A weak acid that appears 99% ionized in bulk fluid at pH 6.5 may encounter a microenvironment closer to pH 5.5 at the membrane surface, shifting the unionized fraction from about 3% to roughly 24%. This microdomain effect is one reason why parallel artificial membrane permeability assays sometimes correlate poorly with in vivo absorption data for weak acids.

When the Model Breaks Down

The biggest limitation anyone working with weak acids at physiological pH needs to accept is that the simple Henderson-Hasselbalch framework only describes thermodynamic equilibrium. It says nothing about kinetics. Membrane permeability, transport protein interactions, and metabolic clearance all operate on timescales that matter. A weak acid might be 99% ionized at pH 7.4, but if it has even modest passive permeability in its unionized form, absorption can still be high. The reverse is also true: a weak acid with pKa near 7.4 exists as a roughly 50:50 mixture, but if the unionized form is actively effluxed by P-glycoprotein, the net absorption can be very low. Buffer capacity is another overlooked factor. Simulated gastric and intestinal fluids used in dissolution testing have limited buffer capacity compared to actual gastrointestinal contents. In vivo, food, bile, pancreatic secretions, and mucin create a much more complex buffering environment. A dissolution test at pH 6.8 with standard phosphate buffer may show complete dissolution, but the same compound in the presence of fed-state contents could precipitate because the local pH shifts differently. I always recommend running at least one dissolution experiment in fed-state simulated intestinal fluid when possible, even if it adds a week to the testing timeline. Finally, strong ionized species at physiological pH face a fundamental barrier for CNS penetration. If your weak acid drug needs to cross the blood-brain barrier, and its pKa keeps it almost entirely ionized at pH 7.4, you should expect very poor brain exposure unless there's a specific transport mechanism. This isn't something you can formulate your way out of. Prodrugs or structural modification to raise the pKa closer to physiological range are the only real options, and each comes with its own development risk.